NEW YORK STATE MEDICAID
PREFERRED DRUG PROGRAM
2013 THERAPEUTIC CLASS RE-REVIEW

The New York State Pharmacy & Therapeutics (P&T) Committee will re-review the following Preferred Drug Program (PDP) therapeutic classes in 2013 (see table below) as new relevant clinical and/or financial information, since the previous review of the class, is known to exist. P&T Committee meeting agendas for 2013 are under development and will be posted on the Department of Health (DoH) web-site thirty (30) days prior to the meeting date.

2013 PDP Re-Review

Therapeutic Category	Therapeutic Classes	Previous Review Date
Analgesics	Opioids – Long Acting	6/15/2012
Anti-Infectives	Hepatitis C – Protease Inhibitors	4/19/2012
	Tetracyclines	4/15/2011
Cardiovascular	Beta Blockers	6/15/2012
	Triglyceride Lowering Agents	4/19/2012
Central Nervous System	Anticonvulsants – Second Generation	11/15/2012
	Carbamazepine Derivatives	11/15/2012
	Multiple Sclerosis Agents	4/15/2011
	Non-Ergot Dopamine Receptor Agonists	6/11/2010
	Sedative Hypnotics/Sleep Agents	4/15/2011
	Selective Serotonin Reuptake Inhibitors	4/19/2012
Endocrine/Metabolic Agents	Anabolic Steroids – Topical	6/15/2012
	Bisphosphonates – Oral	6/16/2011
	Dipeptidyl Peptidase-4 Inhibitors	6/15/2012
	Growth Hormone	11/15/2012
Hematological Agents	Anticoagulants – Injectable	4/29/2010
	Anticoagulants – Oral	4/19/2012
	Platelet Inhibitors	4/19/2012
Immunologic Agents	Immunomodulators – Systemic	6/15/2012

Ophthalmics	NSAIDs	4/15/2011
Renal/Genitourinary	Alpha Reductase Inhibitors for BPH	6/15/2012
	Urinary Tract Antispasmodics	6/15/2012
Respiratory	Anticholinergics – Inhaled	4/19/2012
	Antihistamines – Second Generation	4/15/2011
	Corticosteroids – Inhaled	9/16/2010
	Corticosteroids – Intranasal	6/16/2011

The current preferred and non-preferred status of drugs subject to the PDP may be viewed at https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf

At this time, no relevant new clinical and/or financial information is known to exist for the remaining PDP therapeutic classes since previously reviewed and the DoH proposes no changes to the established Commissioner's final determinations. If interested parties have new relevant clinical information, please submit to the Medicaid Bureau of Pharmacy Policy and Operations (pandtc@health.state.ny.us) in a timely manner. The DoH will consider any new relevant clinical information provided when developing future P&T Committee meeting agendas.

In determining new clinical information, the previous review dates for all therapeutic classes are available on previous meeting agendas which may be viewed at http://www.health.ny.gov/health_care/medicaid/program/ptcommittee/

- New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials (comparative evidence is preferred, or placebo controlled when no head-to-head trials are available). Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of re-review and submission is discouraged.
- Those wishing to submit new clinical information may do so as it becomes available. New information is preferred in an electronic format and may be submitted to pandtc@health.state.ny.us (please reference P&T Committee re-review).
- Clinical information submitted in response to a meeting agenda posted on the P&T Committee web-page must be received by the DoH no later than two (2) weeks prior to the meeting date or the Committee may not have ample time to review the information.

Please continue to monitor the DoH web-site for P&T Committee meeting schedules and agendas (http://www.health.ny.gov/health_care/medicaid/program/pharmacy.htm)

Posted: 3/15/2013